1
|
Marraoui W, Ben Abdallah E, Placide E, Le Bouedec G, Mishellany F. [Nodular PASH of the breast: Radio-clinical presentation, anatomo-pathological correlation and management]. Gynecol Obstet Fertil Senol 2024:S2468-7189(24)00088-6. [PMID: 38518954 DOI: 10.1016/j.gofs.2024.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/25/2024] [Revised: 03/03/2024] [Accepted: 03/13/2024] [Indexed: 03/24/2024]
Affiliation(s)
- Wissam Marraoui
- Service de radiologie et imagerie médicale, CLCC Clermont-Ferrand, centre Jean-Perrin, 58, rue Montalembert, 63000 Clermont-Ferrand cedex 1, France; Délégation recherche clinique et innovation, CLCC Clermont-Ferrand, centre Jean-Perrin, 58, rue Montalembert, 63000 Clermont-Ferrand cedex 1, France.
| | - Elyes Ben Abdallah
- Service de radiologie et imagerie médicale, CLCC Clermont-Ferrand, centre Jean-Perrin, 58, rue Montalembert, 63000 Clermont-Ferrand cedex 1, France
| | - Emmanuel Placide
- Service de radiologie et imagerie médicale, CLCC Clermont-Ferrand, centre Jean-Perrin, 58, rue Montalembert, 63000 Clermont-Ferrand cedex 1, France
| | - Guillaume Le Bouedec
- Service de chirurgie oncologique, CLCC Clermont-Ferrand, centre Jean-Perrin, 58, rue Montalembert, 63000 Clermont-Ferrand cedex 1, France
| | - Florence Mishellany
- Service d'anatomie et cytologie pathologique, CLCC Clermont-Ferrand, centre Jean-Perrin, 58, rue Montalembert, 63000 Clermont-Ferrand cedex 1, France
| |
Collapse
|
2
|
Croce S, Devouassoux-Shisheboran M, Pautier P, Ray-Coquard I, Treilleux I, Neuville A, Arnould L, Just PA, Le Frere Belda MA, Averous G, Leroux A, Bataillon G, Mery E, Loussouarn D, Weinbreck N, Le Guellec S, Mishellany F, Morice P, Guyon F, Genestie C. [Diagnosis of uterine sarcomas and rare uterine mesenchymal tumours with malignant potential. Guidelines of the French Sarcoma Group and Rare Gynaecological Tumours]. Bull Cancer 2024; 111:97-116. [PMID: 37806863 DOI: 10.1016/j.bulcan.2023.08.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2022] [Revised: 08/02/2023] [Accepted: 08/04/2023] [Indexed: 10/10/2023]
Abstract
The landscape of uterine sarcomas is becoming more complex with the description of new entities associated with recurrent driver molecular alterations. Uterine sarcomas, in analogy with soft tissue sarcomas, are distinguished into complex genomic and simple genomic sarcomas. Leiomyosarcomas and undifferentiated uterine sarcomas belong to complex genomic sarcomas group. Low-grade and high-grade endometrial stromal sarcomas, other rare tumors associated with fusion transcripts (such as NTRK, PDGFB, ALK, RET ROS1) and SMARCA4-deficient uterine sarcoma are considered simple genomic sarcomas. The most common uterine sarcoma are first leiomyosarcoma and secondly endometrial stromal sarcomas. Three different histological subtypes of leiomyosarcoma (fusiform, myxoid, epithelioid) are identified, myxoid and epithelioid leiomyosarcoma being more aggressive than fusiform leiomyosarcoma. The distinction between low-grade and high-grade endometrial stromal sarcoma is primarily morphological and immunohistochemical and the detection of fusion transcripts can help the diagnosis. Uterine PEComa is a rare tumor, which is distinguished into borderline and malignant, according to a risk assessment algorithm. Embryonal rhabdomyosarcoma of the uterine cervix is more common in children but can also occur in adult women. Embryonal rhabdomyosarcoma of the uterine cervix is almost always DICER1 mutated, unlike that of the vagina which is wild-type DICER1, and adenosarcoma which can be DICER1 mutated but with less frequency. Among the emerging entities, sarcomas associated with fusion transcripts involving the NTRK, ALK, PDGFB genes benefit from targeted therapy. The integration of molecular data with histology and clinical data allows better identification of uterine sarcomas in order to better treat them.
Collapse
Affiliation(s)
- Sabrina Croce
- Anticancer Center, Institut Bergonié, Department of BioPathology, Bordeaux, France; Unité Inserm U1312, Bordeaux, France; Gynecological pathology group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France.
| | - Mojgan Devouassoux-Shisheboran
- Gynecological pathology group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; CHU de Lyon, Department of Pathology, Lyon, France
| | - Patricia Pautier
- Institut Gustave-Roussy, Department of Medical Oncology, Villejuif, France
| | - Isabelle Ray-Coquard
- Centre Leon-Berard, Department of Medical Oncology, Lyon, France; University Claude-Bernard Lyon I, Laboratoire RESHAPE U1290, Lyon, France
| | - Isabelle Treilleux
- Gynecological pathology group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Centre Leon-Berard, Department of Pathology, Lyon, France
| | - Agnès Neuville
- Gynecological pathology group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Institut de Pathologie de Haut de France, Amiens, France
| | - Laurent Arnould
- Gynecological pathology group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Centre G.-F.-Leclerc, Biology and Tumor Pathology Department, Dijon, France
| | - Pierre-Alexandre Just
- Gynecological pathology group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; AP-HP, Hôpital Cochin, Department of Pathology, Paris, France
| | - Marie Aude Le Frere Belda
- Gynecological pathology group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; AP-HP. Centre, European Georges-Pompidou Hospital, Department of Pathology, Paris, France
| | - Gerlinde Averous
- Gynecological pathology group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; CHRU de Strasbourg, Department of Pathology, Strasbourg, France
| | - Agnès Leroux
- Gynecological pathology group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Institut de Cancérologie de Lorraine, Department of Pathology, Nancy, France
| | - Guillaume Bataillon
- Gynecological pathology group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; CHRU de Strasbourg, Department of Pathology, Strasbourg, France
| | - Eliane Mery
- Gynecological pathology group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; IUCT Oncopole, Department of Pathology, Toulouse, France
| | - Delphine Loussouarn
- Gynecological pathology group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; CHU de Nantes, Department of Pathology, Nantes, France
| | - Nicolas Weinbreck
- Gynecological pathology group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Medipath, Fréjus, France
| | - Sophie Le Guellec
- Gynecological pathology group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Medipath-Les Feuillants, Toulouse, France
| | - Florence Mishellany
- Gynecological pathology group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Centre de Lutte contre le Cancer Jean-Perrin, Department of Pathology, Clermont-Ferrand, France
| | - Philippe Morice
- Gustave-Roussy, Department of Gynecological Surgery, Villejuif, Île-de-France, France
| | - Frédéric Guyon
- Institut Bergonié, Department of surgery, Bordeaux, France
| | - Catherine Genestie
- Gustave-Roussy, Département de Biopathologie, Unité 981, Villejuif, France
| |
Collapse
|
3
|
Croce S, Devouassoux-Shisheboran M, Pautier P, Ray-Coquard I, Treilleux I, Neuville A, Arnould L, Just PA, Belda MALF, Averous G, Leroux A, Mery E, Loussouarn D, Weinbreck N, Le Guellec S, Mishellany F, Morice P, Guyon F, Genestie C. Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group. Gynecol Oncol 2022; 167:373-389. [PMID: 36114030 DOI: 10.1016/j.ygyno.2022.07.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2022] [Revised: 07/26/2022] [Accepted: 07/29/2022] [Indexed: 11/04/2022]
Abstract
The landscape of uterine sarcomas is becoming increasingly complex with the description of new entities associated with recurrent molecular alterations. Uterine sarcomas, as well as soft tissue sarcomas, can be distinguished into complex genomic sarcomas and simple genomic sarcomas. Leiomyosarcoma and pleomorphic type undifferentiated uterine sarcoma belong to the first group. Low-grade and high-grade endometrial stromal sarcomas, NTRK, COL1A1::PDGFB, ALK, RET, ROS1 associated sarcomas, and SMARCA4 deficient uterine sarcoma belong to the second group. Leiomyosarcoma is the most common uterine sarcoma followed by endometrial stromal sarcomas. Three different histologic subtypes of leiomyosarcomas are recognized with distinct diagnostic criteria and different clinical outcomes, the myxoid and epithelioid leiomyosarcomas being even more aggressive than the fusiform type. The distinction between low-grade and high-grade endometrial stromal sarcoma is based first on morphology and immunohistochemistry. The detection of fusion transcripts helps in the diagnosis. Definitely recognized as a separate entity, uterine PEComa is a rare tumor whose diagnostic criteria are being recently defined. Uterine PEComa has a specific algorithm stratifying the tumors into uncertain malignant potential and malignant tumors. Embryonal rhabdomyosarcomas of the uterine cervix are not restricted to children but can also be observed in adult women and are almost always DICER1 mutated, unlike embryonal rhabdomyosarcoma of the vagina which are DICER1wild-type, and adenosarcoma which can be DICER1 mutated but with less frequency. As sarcomas associated with fusion transcripts involving the NTRK, ALK, COL1A1::PDGFB genes can benefit from targeted therapy, systematic detection are now relevant especially for patients with high risk of relapse or in recurrent setting. The integration of molecular data with dedicated expert pathology review for histology and clinical data allows better identification of uterine sarcomas in order to better treat them.
Collapse
Affiliation(s)
- Sabrina Croce
- Department of BioPathology, Anticancer Center, Institut Bergonié, Bordeaux, France; Unité INSERM U1218, Bordeaux, France; Gynecological Pathology Group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France.
| | - Mojgan Devouassoux-Shisheboran
- Gynecological Pathology Group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Department of Pathology, CHU, Lyon, France
| | - Patricia Pautier
- Department of Medical Oncology, Institut Gustave-Roussy, Villejuif, France
| | - Isabelle Ray-Coquard
- Department of Medical Oncology, Centre Leon Berard, Lyon, France; Laboratoire RESHAPE U1290, University Claude Bernard Lyon I, France
| | - Isabelle Treilleux
- Gynecological Pathology Group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Department of Pathology, Centre Leon Berard, Lyon, France
| | - Agnès Neuville
- Gynecological Pathology Group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Institut de Pathologie de Haut de France, Amiens, France
| | - Laurent Arnould
- Gynecological Pathology Group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Biology and Tumor Pathology Department, Centre G-F Leclerc, Dijon, France
| | - Pierre-Alexandre Just
- Gynecological Pathology Group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Department of Pathology, Hopital Cochin, APHP, Paris, France
| | - Marie Aude Le Frere Belda
- Gynecological Pathology Group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Department of Pathology, European Georges Pompidou Hospital, APHP, Centre, Paris, France
| | - Gerlinde Averous
- Gynecological Pathology Group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Department of Pathology, CHRU, Strasbourg, France
| | - Agnès Leroux
- Gynecological Pathology Group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Department of Pathology, Institut de Cancérologie de Lorraine, Nancy, France
| | - Eliane Mery
- Gynecological Pathology Group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Department of Pathology, IUCT Oncopole, Toulouse, France
| | - Delphine Loussouarn
- Gynecological Pathology Group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Department of Pathology, CHU, Nantes, France
| | - Nicolas Weinbreck
- Gynecological Pathology Group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Medipath, Fréjus, France
| | - Sophie Le Guellec
- Gynecological Pathology Group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Medipath-Les Feuillants, Toulouse, France
| | - Florence Mishellany
- Gynecological Pathology Group of RRePS (Réseau de Référence en Pathologie des Sarcomes) Network, France; Department of Pathology, Centre de Lutte contre le Cancer Jean Perrin, Clermont-Ferrand, France
| | - Philippe Morice
- Department of Gynecological Surgery, Gustave Roussy, Villejuif, Île-de-France, France
| | - Frédéric Guyon
- Department of Surgery, Institut Bergonié, Bordeaux, France
| | - Catherine Genestie
- Department de Biopathologie, Gustave Roussy, Unité 981, Villejuif, France
| |
Collapse
|
4
|
Delorme S, Privat M, Sonnier N, Rouanet J, Witkowski T, Kossai M, Mishellany F, Radosevic-Robin N, Juban G, Molnar I, Quintana M, Degoul F. New insight into the role of ANXA1 in melanoma progression: involvement of stromal expression in dissemination. Am J Cancer Res 2021; 11:1600-1615. [PMID: 33948376 PMCID: PMC8085877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Accepted: 12/28/2020] [Indexed: 06/12/2023] Open
Abstract
ANXA1, first described in the context of inflammation, appears to be deregulated in many cancers and increased in melanomas compared with melanocytes. To date, few studies have investigated the role of ANXA1 in melanoma progression. Furthermore, this protein is expressed by various cell types, including immune and endothelial cells. We therefore analyzed the specific roles of ANXA1 using melanoma and stromal cells in two human cell lines (A375-MA2 and SK-MEL-28) in vitro and in Anxa1 null C57Bl6/J mice bearing B16Bl6 tumors. We report decreased proliferation in both ANXA1 siRNA A375-MA2 and SK-MEL-28, but cell-dependent effects of ANXA1 in migration in vitro. However, we also observed a significant decrease of B16Bl6 tumor growth associated with a reduction of Ki-67 positive cells in Anxa1 null mice compared with wild-type mice. Interestingly, we also found a significant reduction of spontaneous metastases, which can be attributed to decreased angiogenesis concomitantly with greater immune cell presence in the Anxa1 null stromal context. This study highlights the pejorative role of ANXA1 in both tumor and stromal cells in melanoma, due to its involvement in proliferation and angiogenesis.
Collapse
Affiliation(s)
- Solène Delorme
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
| | - Maud Privat
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
- Département d’Oncogénétique, Centre Jean PerrinClermont-Ferrand 63000, France
| | - Nicolas Sonnier
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
- Département d’Oncogénétique, Centre Jean PerrinClermont-Ferrand 63000, France
| | - Jacques Rouanet
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
| | - Tiffany Witkowski
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
| | - Myriam Kossai
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
- Département de Pathologie, Centre Jean PerrinClermont-Ferrand 63000, France
| | - Florence Mishellany
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
- Département de Pathologie, Centre Jean PerrinClermont-Ferrand 63000, France
| | - Nina Radosevic-Robin
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
- Département de Pathologie, Centre Jean PerrinClermont-Ferrand 63000, France
| | - Gaëtan Juban
- Institut NeuroMyoGène, Université Claude Bernard Lyon 1, CNRS UMR 5310, INSERM U1217, Université LyonLyon 69008, France
| | - Ioana Molnar
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
- Département de Recherche Clinique et Innovation, Centre Jean PerrinClermont-Ferrand 63000, France
| | - Mercedes Quintana
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
| | - Françoise Degoul
- Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies ThéranostiquesUMR1240, 58 Rue Montalembert, Clermont-Ferrand Cedex 63005, France
| |
Collapse
|
5
|
de Pinieux G, Karanian M, Le Loarer F, Le Guellec S, Chabaud S, Terrier P, Bouvier C, Batistella M, Neuville A, Robin YM, Emile JF, Moreau A, Larousserie F, Leroux A, Stock N, Lae M, Collin F, Weinbreck N, Aubert S, Mishellany F, Charon-Barra C, Croce S, Doucet L, Quintin-Rouet I, Chateau MC, Bazille C, Valo I, Chetaille B, Ortonne N, Brouchet A, Rochaix P, Demuret A, Ghnassia JP, Mescam L, Macagno N, Birtwisle-Peyrottes I, Delfour C, Angot E, Pommepuy I, Ranchere D, Chemin-Airiau C, Jean-Denis M, Fayet Y, Courrèges JB, Mesli N, Berchoud J, Toulmonde M, Italiano A, Le Cesne A, Penel N, Ducimetiere F, Gouin F, Coindre JM, Blay JY. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS One 2021; 16:e0246958. [PMID: 33630918 PMCID: PMC7906477 DOI: 10.1371/journal.pone.0246958] [Citation(s) in RCA: 116] [Impact Index Per Article: 38.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2020] [Accepted: 01/28/2021] [Indexed: 01/20/2023] Open
Abstract
BACKGROUND Since 2010, nationwide networks of reference centers for sarcomas (RREPS/NETSARC/RESOS) collected and prospectively reviewed all cases of sarcomas and connective tumors of intermediate malignancy (TIM) in France. METHODS The nationwide incidence of sarcoma or TIM (2013-2016) was measured using the 2013 WHO classification and confirmed by a second independent review by expert pathologists. Simple clinical characteristics, yearly variations and correlation of incidence with published clinical trials are presented and analyzed. RESULTS Over 150 different histological subtypes are reported from the 25172 patients with sarcomas (n = 18712, 74,3%) or TIM (n = 6460, 25.7%), with n = 5838, n = 6153, n = 6654, and n = 6527 yearly cases from 2013 to 2016. Over these 4 years, the yearly incidence of sarcomas and TIM was therefore 70.7 and 24.4 respectively, with a combined incidence of 95.1/106/year, higher than previously reported. GIST, liposarcoma, leiomyosarcomas, undifferentiated sarcomas represented 13%, 13%, 11% and 11% of tumors. Only GIST, as a single entity had a yearly incidence above 10/106/year. There were respectively 30, 64 and 66 different histological subtypes of sarcomas or TIM with an incidence ranging from 10 to 1/106, 1-0.1/106, or < 0.1/106/year respectively. The 2 latter incidence groups represented 21% of the patients with 130 histotypes. Published phase III and phase II clinical trials (p<10-6) are significantly higher with sarcomas subtypes with an incidence above 1/106 per. CONCLUSIONS This nationwide registry of sarcoma patients, with exhaustive histology review by sarcoma experts, shows that the incidence of sarcoma and TIM is higher than reported, and that tumors with a very low incidence (1<106/year) are less likely to be included in clinical trials.
Collapse
Affiliation(s)
| | - Marie Karanian
- Department of Biopathology, Centre Léon Bérard, Lyon, France
| | | | - Sophie Le Guellec
- Department of Biopathology, Institut Claudius Regaud et Institut Universitaire du Cancer de Toulouse—Oncopôle, Toulouse, France
| | - Sylvie Chabaud
- Department of Biopathology, Centre Léon Bérard, Lyon, France
| | | | - Corinne Bouvier
- Department of pathology, La Timone University Hospital, Marseille, France
| | - Maxime Batistella
- Pathology Department, Saint-Louis Hospital, AP-HP, Université de Paris, Paris, France
| | - Agnès Neuville
- Department of Biopathology, Institut Bergonié, Bordeaux, France
| | - Yves-Marie Robin
- Pôle de Biologie-Pathologie-Génétique Centre Oscar Lambret, & Institut de Pathologie entre Oscar Lambret & CHU Lille, Lille, France
| | | | - Anne Moreau
- Department of Pathology, Department of Orthopedy CHU Nantes, Nantes, France
| | | | - Agnes Leroux
- Department of Biopathology, Institut de Cancérologie de Lorraine—Alexis Vautrin, Vandoeuvre-lès-Nancy, France
| | - Nathalie Stock
- Department of Biopathology, Eugene Marquis Comprehensive Cancer Center & CHU Rennes, Rennes, France
| | - Marick Lae
- Department of Biopathology, Eugene Marquis Comprehensive Cancer Center & CHU Rennes, Rennes, France
- Department of Biopathology, Institut Curie, Paris, France
| | - Francoise Collin
- Department of Biopathology, Centre Georges François Leclerc, Dijon, France
| | | | - Sebastien Aubert
- Pôle de Biologie-Pathologie-Génétique Centre Oscar Lambret, & Institut de Pathologie entre Oscar Lambret & CHU Lille, Lille, France
| | | | | | - Sabrina Croce
- Department of Biopathology, Institut Bergonié, Bordeaux, France
| | | | | | - Marie-Christine Chateau
- Department of Biopathology, Institut de Cancérologie de Montpellier & CHU Montpellier, Montpellier, France
| | - Celine Bazille
- Department of Biopathology, Centre Francois Baclesse, Caen, France
| | - Isabelle Valo
- Department of Pathology, Institut de Cancerologie de l’Ouest, Angers, France
| | | | - Nicolas Ortonne
- Department of Biopathology, Hopital Henri Mondor, Creteil, France
| | - Anne Brouchet
- Department of Biopathology, Institut Claudius Regaud et Institut Universitaire du Cancer de Toulouse—Oncopôle, Toulouse, France
| | - Philippe Rochaix
- Department of Biopathology, Institut Claudius Regaud et Institut Universitaire du Cancer de Toulouse—Oncopôle, Toulouse, France
| | - Anne Demuret
- Department of pathology, CHU de Tours, Tours, France
| | | | - Lenaig Mescam
- Department of Biopathology, Institut Paoli Calmettes, Marseille, France
| | - Nicolas Macagno
- Department of pathology, La Timone University Hospital, Marseille, France
| | | | - Christophe Delfour
- Department of Biopathology, Institut de Cancérologie de Montpellier & CHU Montpellier, Montpellier, France
| | - Emilie Angot
- Department of Biopathology, Eugene Marquis Comprehensive Cancer Center & CHU Rennes, Rennes, France
| | | | | | | | | | - Yohan Fayet
- Department of Biopathology, Centre Léon Bérard, Lyon, France
| | | | - Nouria Mesli
- Department of Biopathology, Institut Bergonié, Bordeaux, France
| | - Juliane Berchoud
- Department of Pathology, Department of Orthopedy CHU Nantes, Nantes, France
| | - Maud Toulmonde
- Department of Biopathology, Institut Bergonié, Bordeaux, France
| | | | - Axel Le Cesne
- Department of Biopathology, Centre Léon Bérard, Lyon, France
| | - Nicolas Penel
- Pôle de Biologie-Pathologie-Génétique Centre Oscar Lambret, & Institut de Pathologie entre Oscar Lambret & CHU Lille, Lille, France
| | | | - Francois Gouin
- Department of Biopathology, Centre Léon Bérard, Lyon, France
| | | | - Jean-Yves Blay
- Department of Biopathology, Centre Léon Bérard, Lyon, France
- Department of Medicine of Centre Leon Berard, University Claude Bernard Lyon I, Lyon, France
- Headquarters, Unicancer, Paris, France
- * E-mail:
| | | |
Collapse
|
6
|
Lesluyes T, Baud J, Pérot G, Charon-Barra C, You A, Valo I, Bazille C, Mishellany F, Leroux A, Renard-Oldrini S, Terrier P, Le Cesne A, Laé M, Piperno-Neumann S, Bonvalot S, Neuville A, Collin F, Maingon P, Coindre JM, Chibon F. Genomic and transcriptomic comparison of post-radiation versus sporadic sarcomas. Mod Pathol 2019; 32:1786-1794. [PMID: 31243333 DOI: 10.1038/s41379-019-0300-2] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2019] [Revised: 05/07/2019] [Accepted: 05/08/2019] [Indexed: 01/16/2023]
Abstract
Post-radiation sarcomas are rare secondary cancers arising from radiation therapies. To date, few genetic specificities have been described for such malignancies and the oncogenesis of sarcomas with complex genetics (both sporadic and post-radiation) remains largely misunderstood. We performed genomic and transcriptomic analyses on 77 post-radiation sarcomas using DNA-array and RNA sequencing. Consequently, we were able to investigate changes in copy number variations, transcriptome profiling, fusion gene expression, and mutational landscapes. We compare these data to a reference cohort of 93 sporadic sarcomas. At genomic level, similar chromosomal complexity was observed both in post-radiation and sporadic sarcomas with complex genetics. We found more frequent CDKN2A and CDKN2B (coding for p14/p16 and p15 proteins, respectively; at 9p21.3) losses in post-radiation (71%) than in sporadic tumors (39%; P = 6.92e-3). Among all detected fusion genes and punctual variations, few specificities were observed between these groups and such alterations are not able to drive a strong and specific oncogenesis. Recurrent MYC amplifications (96%) and KDR variants (8%) were detected in post-radiation angiosarcomas, in agreement with the literature. Transcriptomic analysis of such angiosarcomas revealed two distinct groups harboring different genomic imbalances (in particular gains of 17q24.2-17qter) with different clinical courses according to patient's vital status. Differential gene expression analysis permitted to focus on the immune response as a potential actor to tumor aggressiveness. Histochemistry validated a lower inflammation and lower immune infiltrate at tumor periphery for highly aggressive angiosarcomas. Our results provide new genomic and transcriptomic information about post-radiation sarcomas. The techniques we used (RNA-seq and DNA-arrays) did not highlight major differences in sarcomas with complex genetics depending on the radiation context, revealing similar patterns of transcriptomic profiles and chromosomal copy number variations. Additional characterizations, particularly whole genome sequencing, could measure changes in DNA following radiation therapy in such malignancies and may precise their oncogenesis.
Collapse
Affiliation(s)
- Tom Lesluyes
- Inserm U1218, Institut Bergonié, Bordeaux, France.,University of Bordeaux, F-33000, Bordeaux, France.,Inserm UMR1037, Cancer Research Center of Toulouse, Toulouse, France.,Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France
| | - Jessica Baud
- Inserm U1218, Institut Bergonié, Bordeaux, France.,University of Bordeaux, F-33000, Bordeaux, France
| | - Gaëlle Pérot
- Inserm U1218, Institut Bergonié, Bordeaux, France.,Department of Pathology, Institut Bergonié, Bordeaux, France
| | | | - Axel You
- Inserm U1218, Institut Bergonié, Bordeaux, France.,University of Nantes, F-44000, Nantes, France
| | - Isabelle Valo
- Department of Pathology, Institut de cancérologie de l'Ouest site Paul Papin, Angers, France
| | - Céline Bazille
- Department of Pathology, University Hospital, Caen, France
| | | | - Agnès Leroux
- Department of Pathology, Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, France
| | - Sophie Renard-Oldrini
- Department of Radiation Therapy, Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, France
| | - Philippe Terrier
- Department of Pathology, Institut Gustave Roussy, Villejuif, France
| | - Axel Le Cesne
- Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
| | - Marick Laé
- Department of Pathology, Institut Curie, Paris, France.,Department of Pathology, Centre Henri Becquerel, Inserm U1245, UniRouen Normandy University, Rouen, France
| | | | | | - Agnès Neuville
- Department of Pathology, Institut Bergonié, Bordeaux, France.,Contades Office of Pathological Anatomy and Cytology, Strasbourg, France
| | - Françoise Collin
- Department of Pathology, Centre Georges-François Leclerc, Dijon, France
| | - Philippe Maingon
- Department of Radiation Oncology, Hôpital La Pitié-Salpêtrière, Sorbonne University, Paris, France
| | - Jean-Michel Coindre
- University of Bordeaux, F-33000, Bordeaux, France.,Department of Pathology, Institut Bergonié, Bordeaux, France
| | - Frédéric Chibon
- Inserm UMR1037, Cancer Research Center of Toulouse, Toulouse, France. .,Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.
| |
Collapse
|
7
|
Judes G, Dubois L, Rifaï K, Idrissou M, Mishellany F, Pajon A, Besse S, Daures M, Degoul F, Bignon YJ, Penault-Llorca F, Bernard-Gallon D. TIP60: an actor in acetylation of H3K4 and tumor development in breast cancer. Epigenomics 2018; 10:1415-1430. [PMID: 30324811 DOI: 10.2217/epi-2018-0004] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
AIM The acetyltransferase TIP60 is reported to be downregulated in several cancers, in particular breast cancer, but the molecular mechanisms resulting from its alteration are still unclear. MATERIALS & METHODS In breast tumors, H3K4ac enrichment and its link with TIP60 were evaluated by chromatin immunoprecipitation-qPCR and re-chromatin immunoprecipitation techniques. To assess the biological roles of TIP60 in breast cancer, two cell lines of breast cancer, MDA-MB-231 (ER-) and MCF-7 (ER+) were transfected with shRNA specifically targeting TIP60 and injected to athymic Balb-c mice. RESULTS We identified a potential target of TIP60, H3K4. We show that an underexpression of TIP60 could contribute to a reduction of H3K4 acetylation in breast cancer. An increase in tumor development was noted in sh-TIP60 MDA-MB-231 xenografts and a slowdown of tumor growth in sh-TIP60 MCF-7 xenografts. CONCLUSION This is evidence that the underexpression of TIP60 observed in breast cancer can promote the tumorigenesis of ER-negative tumors.
Collapse
Affiliation(s)
- Gaëlle Judes
- Department of Oncogenetics, Centre Jean Perrin, CBRV, 28 Place Henri-Dunant, 63001, Clermont-Ferrand, France.,INSERM U 1240, IMOST, University Clermont Auvergne, 58 rue Montalembert-BP184, 63005 Clermont-Ferrand, France
| | - Lucas Dubois
- Department of Oncogenetics, Centre Jean Perrin, CBRV, 28 Place Henri-Dunant, 63001, Clermont-Ferrand, France.,INSERM U 1240, IMOST, University Clermont Auvergne, 58 rue Montalembert-BP184, 63005 Clermont-Ferrand, France
| | - Khaldoun Rifaï
- Department of Oncogenetics, Centre Jean Perrin, CBRV, 28 Place Henri-Dunant, 63001, Clermont-Ferrand, France.,INSERM U 1240, IMOST, University Clermont Auvergne, 58 rue Montalembert-BP184, 63005 Clermont-Ferrand, France
| | - Mouhamed Idrissou
- Department of Oncogenetics, Centre Jean Perrin, CBRV, 28 Place Henri-Dunant, 63001, Clermont-Ferrand, France.,INSERM U 1240, IMOST, University Clermont Auvergne, 58 rue Montalembert-BP184, 63005 Clermont-Ferrand, France
| | - Florence Mishellany
- INSERM U 1240, IMOST, University Clermont Auvergne, 58 rue Montalembert-BP184, 63005 Clermont-Ferrand, France.,Department of Biopathology, Centre Jean Perrin, 58 rue Montalembert, 63011, Clermont-Ferrand, France
| | - Amaury Pajon
- Department of Oncogenetics, Centre Jean Perrin, CBRV, 28 Place Henri-Dunant, 63001, Clermont-Ferrand, France.,INSERM U 1240, IMOST, University Clermont Auvergne, 58 rue Montalembert-BP184, 63005 Clermont-Ferrand, France
| | - Sophie Besse
- INSERM U 1240, IMOST, University Clermont Auvergne, 58 rue Montalembert-BP184, 63005 Clermont-Ferrand, France
| | - Marine Daures
- Department of Oncogenetics, Centre Jean Perrin, CBRV, 28 Place Henri-Dunant, 63001, Clermont-Ferrand, France.,INSERM U 1240, IMOST, University Clermont Auvergne, 58 rue Montalembert-BP184, 63005 Clermont-Ferrand, France
| | - Françoise Degoul
- INSERM U 1240, IMOST, University Clermont Auvergne, 58 rue Montalembert-BP184, 63005 Clermont-Ferrand, France
| | - Yves-Jean Bignon
- Department of Oncogenetics, Centre Jean Perrin, CBRV, 28 Place Henri-Dunant, 63001, Clermont-Ferrand, France.,INSERM U 1240, IMOST, University Clermont Auvergne, 58 rue Montalembert-BP184, 63005 Clermont-Ferrand, France
| | - Frédérique Penault-Llorca
- INSERM U 1240, IMOST, University Clermont Auvergne, 58 rue Montalembert-BP184, 63005 Clermont-Ferrand, France.,Department of Biopathology, Centre Jean Perrin, 58 rue Montalembert, 63011, Clermont-Ferrand, France
| | - Dominique Bernard-Gallon
- Department of Oncogenetics, Centre Jean Perrin, CBRV, 28 Place Henri-Dunant, 63001, Clermont-Ferrand, France.,INSERM U 1240, IMOST, University Clermont Auvergne, 58 rue Montalembert-BP184, 63005 Clermont-Ferrand, France
| |
Collapse
|
8
|
Croce S, Ducoulombier A, Ribeiro A, Lesluyes T, Noel JC, Amant F, Guillou L, Stoeckle E, Devouassoux-Shisheboran M, Penel N, Floquet A, Arnould L, Guyon F, Mishellany F, Chakiba C, Cuppens T, Zikan M, Leroux A, Frouin E, Farre I, Genestie C, Valo I, MacGrogan G, Chibon F. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors. Mod Pathol 2018; 31:816-828. [PMID: 29327710 DOI: 10.1038/modpathol.2017.185] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2017] [Revised: 11/10/2017] [Accepted: 11/12/2017] [Indexed: 12/15/2022]
Abstract
The diagnosis of a uterine smooth muscle lesion is, in the majority of cases, straightforward. However, in a small number of cases, the morphological criteria used in such lesions cannot differentiate with certainty a benign from a malignant lesion and a diagnosis of smooth muscle tumor with uncertain malignant potential (STUMP) is made. Uterine leiomyosarcomas are often easy to diagnose but it is difficult or even impossible to identify a prognostic factor at the moment of the diagnosis with the exception of the stage. We hypothesize, for uterine smooth muscle lesions, that there is a gradient of genomic complexity that correlates to outcome. We first tested this hypothesis on STUMP lesions in a previous study and demonstrated that this 'gray category' could be split according to genomic index into two groups. A benign group, with a low to moderate alteration rate without recurrence and a malignant group, with a highly rearranged profile akin to uterine leiomyosarcomas. Here, we analyzed a large series of 77 uterine smooth muscle lesions (from 76 patients) morphologically classified as 19 leiomyomas, 14 STUMP and 44 leiomyosarcomas with clinicopathological and genomic correlations. We confirmed that genomic index with a cut-off=10 is a predictor of recurrence (P<0.0001) and with a cut-off=35 is a marker for poor overall survival (P=0.035). For the tumors confined to the uterus, stage as a prognostic factor was not useful in survival prediction. At stage I, among the tumors reclassified as molecular leiomyosarcomas (ie, genomic index ≥10), the poor prognostic markers were: 5p gain (overall survival P=0.0008), genomic index at cut-off=35 (overall survival P=0.0193), 13p loss including RB1 (overall survival P=0.0096) and 17p gain including MYOCD gain (overall survival P=0.0425). Based on these findings (and the feasibility of genomic profiling by array-comparative genomic hybridization), genomic index, 5p and 17p gains prognostic value could be evaluated in future prospective chemotherapy trials.
Collapse
Affiliation(s)
- Sabrina Croce
- Department of Biopathology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France.,Institut National de la Santé et de la Recherche Medicale (INSERM) U1218, Bordeaux, France
| | - Agnès Ducoulombier
- Oncology Department, Centre Oscar Lambret, Comprehensive Cancer Centre, Lille, France.,Oncology Department, Centre Antoine Lacassagne, Comprehensive Cancer Centre, Nice, France
| | - Agnès Ribeiro
- Department of Biopathology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France
| | - Tom Lesluyes
- Institut National de la Santé et de la Recherche Medicale (INSERM) U1218, Bordeaux, France.,University of Bordeaux, Bordeaux, France
| | - Jean-Christophe Noel
- Department of Pathology, Clinic of Gynecopathology and Senology, Erasme University Hospital, Brussels, Belgium
| | - Frédéric Amant
- KU Leuven - University of Leuven, Department of Oncology, Gynaecologic Oncology; University Hospitals Leuven, Department of Obstetrics and Gynaecology, Leuven, Belgium.,Centre for Gynecologic Oncology Amsterdam (CGOA), Antoni Van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Louis Guillou
- Argot-Lab, Lausanne, Switzerland.,Institut Universitaire de Pathologie, Lausanne, Switzerland
| | - Eberhard Stoeckle
- Department of Surgery, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France
| | | | - Nicolas Penel
- Oncology Department, Centre Oscar Lambret, Comprehensive Cancer Centre, Lille, France
| | - Anne Floquet
- Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France
| | - Laurent Arnould
- Department of Pathology, Centre JF Leclerc, Comprehensive Cancer Centre, Dijon, France
| | - Frédéric Guyon
- Department of Surgery, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France
| | - Florence Mishellany
- Department of Pathology, Centre Jean Perrin, Comprehensive Cancer Centre, Clermont-Ferrand, France
| | - Camille Chakiba
- Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France
| | - Tine Cuppens
- KU Leuven - University of Leuven, Department of Oncology, Gynaecologic Oncology; University Hospitals Leuven, Department of Obstetrics and Gynaecology, Leuven, Belgium
| | - Michal Zikan
- Gynaecological Oncology Center, Department of Obstetrics and Gynaecology, Charles University in Prague - First Faculty of Medicine and General University Hospital, Prague, Czech Republic
| | - Agnès Leroux
- Department of Pathology, Centre Alexis Vautrin, Comprehensive Cancer Centre, Vandoeuvre-les Nancy, France
| | - Eric Frouin
- Department of Pathology, University Hospital, Poitiers, France
| | - Isabelle Farre
- Department of Pathology, Centre Oscar Lambret, Comprehensive Cancer Centre, Lille, France
| | - Catherine Genestie
- Department of Pathology, Institut Gustave Roussy, Comprehensive Cancer Centre, Villejuif, France
| | - Isabelle Valo
- Department of Pathology, ICO Site Paul Papin, Comprehensive Cancer Centre, Angers, France
| | - Gaëtan MacGrogan
- Department of Biopathology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France
| | - Frédéric Chibon
- Department of Biopathology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France.,Institut National de la Santé et de la Recherche Medicale (INSERM) U1218, Bordeaux, France
| |
Collapse
|
9
|
Viallard C, Chezal JM, Mishellany F, Ranchon-Cole I, Pereira B, Herbette A, Besse S, Boudhraa Z, Jacquemot N, Cayre A, Miot-Noirault E, Sun JS, Dutreix M, Degoul F. Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy. Oncotarget 2017; 7:12927-36. [PMID: 26887045 PMCID: PMC4914332 DOI: 10.18632/oncotarget.7340] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2015] [Accepted: 01/24/2016] [Indexed: 01/15/2023] Open
Abstract
Radiolabelled melanin ligands offer an interesting strategy for the treatment of disseminated pigmented melanoma. One of these molecules, ICF01012 labelled with iodine 131, induced a significant slowing of melanoma growth. Here, we have explored the combination of [131I]ICF01012 with coDbait, a DNA repair inhibitor, to overcome melanoma radioresistance and increase targeted radionuclide therapy (TRT) efficacy. In human SK-Mel 3 melanoma xenograft, the addition of coDbait had a synergistic effect on tumor growth and median survival. The anti-tumor effect was additive in murine syngeneic B16Bl6 model whereas coDbait combination with [131I]ICF01012 did not increase TRT side effects in secondary pigmented tissues (e.g. hair follicles, eyes). Our results confirm that DNA lesions induced by TRT were not enhanced with coDbait association but, the presence of micronuclei and cell cycle blockade in tumor shows that coDbait acts by interrupting or delaying DNA repair. In this study, we demonstrate for the first time, the usefulness of DNA repair traps in the context of targeted radionuclide therapy.
Collapse
Affiliation(s)
- Claire Viallard
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France.,Inserm, U 990, F-63000 Clermont-Ferrand, France
| | - Jean-Michel Chezal
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France.,Inserm, U 990, F-63000 Clermont-Ferrand, France
| | - Florence Mishellany
- Anatomopathology Department, Centre Jean Perrin, Comprehensive Cancer Center, 63011 Clermont-Ferrand, France
| | - Isabelle Ranchon-Cole
- Clermont Université, Université d'Auvergne, UFR Pharmacie Laboratoire de Biophysique Neurosensorielle, Inserm U 1107, F-63001 Clermont-Ferrand, France
| | | | - Aurélie Herbette
- CNRS-UMR3347, INSERMU1021, Institut Curie, Université Paris Sud, Bat 110, Centre Universitaire 91405 Orsay, Cedex, France
| | - Sophie Besse
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France.,Inserm, U 990, F-63000 Clermont-Ferrand, France
| | - Zied Boudhraa
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France.,Inserm, U 990, F-63000 Clermont-Ferrand, France
| | - Nathalie Jacquemot
- Clermont Université, Université d'Auvergne, UFR Pharmacie Laboratoire de Biophysique Neurosensorielle, Inserm U 1107, F-63001 Clermont-Ferrand, France
| | - Anne Cayre
- Anatomopathology Department, Centre Jean Perrin, Comprehensive Cancer Center, 63011 Clermont-Ferrand, France
| | - Elisabeth Miot-Noirault
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France.,Inserm, U 990, F-63000 Clermont-Ferrand, France
| | | | - Marie Dutreix
- CNRS-UMR3347, INSERMU1021, Institut Curie, Université Paris Sud, Bat 110, Centre Universitaire 91405 Orsay, Cedex, France
| | - Françoise Degoul
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, F-63000 Clermont-Ferrand, France.,Inserm, U 990, F-63000 Clermont-Ferrand, France
| |
Collapse
|
10
|
Rbah-Vidal L, Vidal A, Billaud EMF, Besse S, Ranchon-Cole I, Mishellany F, Perrot Y, Maigne L, Moins N, Guerquin-Kern JL, Degoul F, Chezal JM, Auzeloux P, Miot-Noirault E. Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy. Neoplasia 2016; 19:17-27. [PMID: 27987437 PMCID: PMC5157796 DOI: 10.1016/j.neo.2016.11.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2016] [Accepted: 11/01/2016] [Indexed: 01/05/2023] Open
Abstract
PURPOSE: This work reports, in melanoma models, the theranostic potential of ICF15002 as a single fluorinated and iodinated melanin-targeting compound. METHODS: Studies were conducted in the murine syngeneic B16BL6 model and in the A375 and SK-MEL-3 human xenografts. ICF15002 was radiolabeled with fluorine-18 for positron emission tomography (PET) imaging and biodistribution, with iodine-125 for metabolism study, and iodine-131 for targeted radionuclide therapy (TRT). TRT efficacy was assessed by tumor volume measurement, with mechanistics and dosimetry parameters being determined in the B16BL6 model. Intracellular localization of ICF15002 was characterized by secondary ion mass spectrometry (SIMS). RESULTS: PET imaging with [18F]ICF15002 evidenced tumoral uptake of 14.33 ± 2.11%ID/g and 4.87 ± 0.93%ID/g in pigmented B16BL6 and SK-MEL-3 models, respectively, at 1 hour post inoculation. No accumulation was observed in the unpigmented A375 melanoma. SIMS demonstrated colocalization of ICF15002 signal with melanin polymers in melanosomes of the B16BL6 tumors. TRT with two doses of 20 MBq [131I]ICF15002 delivered an absorbed dose of 102.3 Gy to B16BL6 tumors, leading to a significant tumor growth inhibition [doubling time (DT) of 2.9 ± 0.5 days in treated vs 1.8 ± 0.3 in controls] and a prolonged median survival (27 days vs 21 in controls). P53S15 phosphorylation and P21 induction were associated with a G2/M blockage, suggesting mitotic catastrophe. In the human SK-MEL-3 model, three doses of 25 MBq led also to a DT increase (26.5 ± 7.8 days vs 11.0 ± 3.8 in controls) and improved median survival (111 days vs 74 in controls). CONCLUSION: Results demonstrate that ICF15002 fulfills suitable properties for bimodal imaging/TRT management of patients with pigmented melanoma.
Collapse
Affiliation(s)
- Latifa Rbah-Vidal
- UMR 990 INSERM/Université d'Auvergne, F-63005 Clermont-Ferrand, France; UMR 892 INSERM/6299 CNRS/Université de Nantes, F-44007 Nantes, France
| | - Aurélien Vidal
- UMR 990 INSERM/Université d'Auvergne, F-63005 Clermont-Ferrand, France; Arronax, CS 10112, F-44817 Saint Herblain Cedex, France
| | | | - Sophie Besse
- UMR 990 INSERM/Université d'Auvergne, F-63005 Clermont-Ferrand, France
| | - Isabelle Ranchon-Cole
- UMR 1107 INSERM/Université d'Auvergne, Equipe Biophysique Neurosensorielle, F-63000 Clermont-Ferrand, France
| | - Florence Mishellany
- Centre Jean Perrin, Laboratoire d'anatomo-pathologie, F-63011 Clermont-Ferrand, France
| | - Yann Perrot
- CNRS/IN2P3/Université Blaise Pascal, Laboratoire de Physique Corpusculaire, F-63000 Clermont-Ferrand, France
| | - Lydia Maigne
- CNRS/IN2P3/Université Blaise Pascal, Laboratoire de Physique Corpusculaire, F-63000 Clermont-Ferrand, France
| | - Nicole Moins
- UMR 990 INSERM/Université d'Auvergne, F-63005 Clermont-Ferrand, France
| | | | - Françoise Degoul
- UMR 990 INSERM/Université d'Auvergne, F-63005 Clermont-Ferrand, France
| | | | - Philippe Auzeloux
- UMR 990 INSERM/Université d'Auvergne, F-63005 Clermont-Ferrand, France
| | | |
Collapse
|
11
|
Viallard C, Perrot Y, Boudhraa Z, Jouberton E, Miot-Noirault E, Bonnet M, Besse S, Mishellany F, Cayre A, Maigne L, Rbah-Vidal L, D'Incan M, Cachin F, Chezal JM, Degoul F. [¹²³I]ICF01012 melanoma imaging and [¹³¹I]ICF01012 dosimetry allow adapted internal targeted radiotherapy in preclinical melanoma models. Eur J Dermatol 2015; 25:29-35. [PMID: 25548082 DOI: 10.1684/ejd.2014.2481] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND Melanin-targeting radiotracers are interesting tools for imaging and treatment of pigmented melanoma metastases. However, variation of the pigment concentration may alter the efficiency of such targeting. OBJECTIVES A clear assessment of both tumor melanin status and dosimetry are therefore prerequisites for internal radiotherapy of disseminated melanoma. MATERIALS & METHODS The melanin tracer ICF01012 was labelled with iodine-123 for melanoma imaging in pigmented murine B16F0 and human SK-Mel 3 melanomas. RESULTS In vivo imaging showed that the uptake of [(123)I]ICF01012 to melanomas correlated significantly with melanin content. Schedule treatment of 3 × 25 MBq [(131)I]ICF01012 significantly reduced SK-Mel 3 tumor growth and significantly increased the median survival in treated mice. For this protocol, the calculated delivered dose was 53.2 Gy. CONCLUSION Radio-iodinated ICF01012 is a good candidate for both imaging and therapeutic purposes for patients with metastatic pigmented melanomas.
Collapse
Affiliation(s)
- Claire Viallard
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, Inserm, U 990, F-63000 Clermont-Ferrand, France
| | - Yann Perrot
- Clermont Université, Université Blaise Pascal, CNRS/IN2P3, Laboratoire de Physique Corpusculaire, BP 10448, F-63000 Clermont-Ferrand, France
| | - Zied Boudhraa
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, Inserm, U 990, F-63000 Clermont-Ferrand, France
| | | | - Elisabeth Miot-Noirault
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, Inserm, U 990, F-63000 Clermont-Ferrand, France
| | - Mathilde Bonnet
- U1071 INSERM Université d'Auvergne, M2iSH Clermont-Ferrand, F-63000, France
| | - Sophie Besse
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, Inserm, U 990, F-63000 Clermont-Ferrand, France
| | | | - Anne Cayre
- Centre Jean Perrin, Clermont-Ferrand, F-63011, France
| | - Lydia Maigne
- Clermont Université, Université Blaise Pascal, CNRS/IN2P3, Laboratoire de Physique Corpusculaire, BP 10448, F-63000 Clermont-Ferrand, France
| | - Latifa Rbah-Vidal
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, Inserm, U 990, F-63000 Clermont-Ferrand, France
| | - Michel D'Incan
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, Inserm, U 990, F-63000 Clermont-Ferrand, France
| | | | - Jean-Michel Chezal
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, Inserm, U 990, F-63000 Clermont-Ferrand, France
| | - Françoise Degoul
- Clermont Université, Université d'Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, BP 10448, Inserm, U 990, F-63000 Clermont-Ferrand, France
| |
Collapse
|
12
|
Viallard C, Chezal JM, Boudhraa Z, Mishellany F, Ranchon-Cole I, Besse S, Miot-Noirault E, D’Incan M, Cachin F, Dutreix M, Degoul F. Traitement du mélanome métastasé par radiothérapie interne vectorisée : mécanismes et potentialisation. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.04.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
13
|
Gadea E, Thivat E, Paulon R, Mishellany F, Gimbergues P, Capel F, Mosoni L, Merlin C, Lombès M, Morio B, Durando X. Hibernoma: a clinical model for exploring the role of brown adipose tissue in the regulation of body weight? J Clin Endocrinol Metab 2014; 99:1-6. [PMID: 24152683 DOI: 10.1210/jc.2013-2829] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT Hibernoma is a rare benign tumor histologically similar to brown adipose tissue. Some studies reported weight loss in patients with this tumor; however, the mechanisms have never been investigated. OBJECTIVE The purpose of this study is to explore the impact of hibernoma resection on the whole-body metabolism. PATIENT AND METHODS A 68-year-old woman was examined after a weight loss of 10 kg in 6 months. Body composition, food intake, physical activity, blood levels of thyroid hormones, and lipid profile were assessed before surgery and during 1 year after surgery. The patient's resting energy expenditure (REE) over time was compared to a control group of 18 matched healthy volunteers. RESULTS Within 1 year after hibernoma resection, the patient gained 15 kg of body weight. This was associated with fat mass gain (+41%), mainly in the abdominal region (+48%). The patient also developed hepatic nonalcoholic steatosis, mild hypertriglyceridemia, and reduced levels of high-density lipoproteins. REE increased during the dynamic phase of weight gain, compared to the presurgery measurement, and returned to baseline after 1 year. Food intake was increased by 37.5% 6 weeks after resection of the hibernoma and returned to baseline values within 6 months. CONCLUSIONS In our study conditions, hibernoma did not alter REE, but weight gain did. Specific physical activities and dietetic follow-ups are suggested for those patients to prevent excess fat mass gain and metabolic disorders after hibernoma resection. More studies should focus on hibernoma mechanisms inducing weight loss.
Collapse
Affiliation(s)
- Emilie Gadea
- Centre Jean Perrin (E.G., E.T., R.P., F.M., P.G., C.M., X.D.), Clermont-Ferrand F-63011, France; Institut National de la Recherche Agronomique (E.G., F.C., L.M., B.M.), Unité Mixte de Recherche (UMR) 1019, Unité de Nutrition Humaine (UNH), Centre de Recherche en Nutrition Humaine d'Auvergne, F-63000 Clermont-Ferrand, France; Clermont University (E.G., B.M.), University of Auvergne, UNH, BP 10448, F-63000 Clermont-Ferrand, France; Centre d'Investigation Clinique (E.G., E.T., X.D.), Inserm U501, Clermont-Ferrand, F-63000, France; EA 4677 Equipe de Recherche sur les Traitements Individualisés des Cancers (E.T.), F-63011 Clermont-Ferrand, France; Inserm (M.L.), Univ Paris-Sud 11, Faculté de Médecine Paris-Sud, UMR-S693, Le Kremlin Bicêtre, F-94276, France; and Translational Oncology EA3846 (X.D.), University of Auvergne, F-63000 Clermont-Ferrand, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Penault-Llorca F, Mishellany F, Fouilhoux G, Trechot I, Maury F, Robin N, Cayre A, Dauplat MM. [Diagnostic approach for breast cancer classification]. Rev Prat 2013; 63:1384-1390. [PMID: 24579333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
The pathologist is involved at various steps in the management of a patient with breast cancer and in the therapeutic decision. First, the pathologist confirms a diagnosis of malignancy on cytology specimens, microbiopsies and surgical specimens. During the surgery, through the frozen section, the pathologist specifies the surgical limits and collects specimens for research purposes. Then the pathologist evaluates the parameters needed to establish the final diagnosis, the prognosis and the identification of predictive factors, using ancillary techniques such as immunohistochemistry, in situ hybridization or molecular techniques. Mandatory elements to be included in the final pathological report are size, histological type, SBR grade modified by Elston and Ellis, the presence or absence of vascular or lymphatic peritumoral emboli (prognostic parameters), the status of resection margins (local relapse risk) and the status of hormonal receptor and HER2 (predictive parameters).
Collapse
Affiliation(s)
- Frédérique Penault-Llorca
- Département de pathologie et de biopathologie, centre Jean-Perrin, 63011 Clermont-Ferrand Cedex, France.
| | - Florence Mishellany
- Département de pathologie et de biopathologie, centre Jean-Perrin, 63011 Clermont-Ferrand Cedex, France
| | - Geneviève Fouilhoux
- Département de pathologie et de biopathologie, centre Jean-Perrin, 63011 Clermont-Ferrand Cedex, France
| | - Isabelle Trechot
- Département de pathologie et de biopathologie, centre Jean-Perrin, 63011 Clermont-Ferrand Cedex, France
| | - Florence Maury
- Département de pathologie et de biopathologie, centre Jean-Perrin, 63011 Clermont-Ferrand Cedex, France
| | - Nina Robin
- Département de pathologie et de biopathologie, centre Jean-Perrin, 63011 Clermont-Ferrand Cedex, France
| | - Anne Cayre
- Département de pathologie et de biopathologie, centre Jean-Perrin, 63011 Clermont-Ferrand Cedex, France
| | - Marie-Mélanie Dauplat
- Département de pathologie et de biopathologie, centre Jean-Perrin, 63011 Clermont-Ferrand Cedex, France
| |
Collapse
|
15
|
Lamas B, Nachat‐Kappes R, Goncalves‐Mendes N, Mishellany F, Rossary A, Vasson M, Farges M. Dietary fat without body weight gain increases in vivo MCF‐7 human breast cancer cell growth and decreases natural killer cell cytotoxicity. Mol Carcinog 2013; 54:58-71. [DOI: 10.1002/mc.22074] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2012] [Revised: 06/22/2013] [Accepted: 07/02/2013] [Indexed: 12/15/2022]
Affiliation(s)
- Bruno Lamas
- Clermont Université, Université d'Auvergne, Unité de Nutrition Humaine, Equipe ECREIN, CLARA, CRNH AuvergneINRA, UMR 1019Clermont‐FerrandFrance
| | - Rachida Nachat‐Kappes
- Clermont Université, Université d'Auvergne, Unité de Nutrition Humaine, Equipe ECREIN, CLARA, CRNH AuvergneINRA, UMR 1019Clermont‐FerrandFrance
| | - Nicolas Goncalves‐Mendes
- Clermont Université, Université d'Auvergne, Unité de Nutrition Humaine, Equipe ECREIN, CLARA, CRNH AuvergneINRA, UMR 1019Clermont‐FerrandFrance
| | - Florence Mishellany
- EA 4677 ERTICa, Service d'Anatomopathologie, Centre de Lutte Contre le Cancer Jean PerrinClermont‐FerrandFrance
| | - Adrien Rossary
- Clermont Université, Université d'Auvergne, Unité de Nutrition Humaine, Equipe ECREIN, CLARA, CRNH AuvergneINRA, UMR 1019Clermont‐FerrandFrance
| | - Marie‐Paule Vasson
- Clermont Université, Université d'Auvergne, Unité de Nutrition Humaine, Equipe ECREIN, CLARA, CRNH AuvergneINRA, UMR 1019Clermont‐FerrandFrance
- Centre de Lutte Contre le Cancer Jean PerrinUnité de NutritionClermont‐FerrandFrance
- CHU Clermont‐Ferrand, Unité de NutritionClermont‐FerrandFrance
| | - Marie‐Chantal Farges
- Clermont Université, Université d'Auvergne, Unité de Nutrition Humaine, Equipe ECREIN, CLARA, CRNH AuvergneINRA, UMR 1019Clermont‐FerrandFrance
| |
Collapse
|
16
|
Dauplat MM, Mishellany F, Radosevic-Robin N, Tréchot I, Tixier L, Penault-Llorca F. Analyse peropératoire et définitive du ganglion sentinelle (GS), classification de l’atteinte ganglionnaire. ONCOLOGIE 2013. [DOI: 10.1007/s10269-013-2291-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
17
|
Degoul F, Borel M, Jacquemot N, Besse S, Communal Y, Mishellany F, Papon J, Penault-Llorca F, Donnarieix D, Doly M, Maigne L, Miot-Noirault E, Cayre A, Cluzel J, Moins N, Chezal JM, Bonnet M. In vivo efficacy of melanoma internal radionuclide therapy with a 131I-labelled melanin-targeting heteroarylcarboxamide molecule. Int J Cancer 2013; 133:1042-53. [PMID: 23404099 DOI: 10.1002/ijc.28103] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2012] [Accepted: 01/23/2013] [Indexed: 01/10/2023]
Abstract
The development of alternative therapies for melanoma treatment is of great interest as long-term tumour regression is not achieved with new targeted chemotherapies on selected patients. We previously demonstrated that radioiodinated heteroarylcarboxamide ([131I]ICF01012) induced a strong anti-tumoural effect by inhibiting both primary tumour growth and dissemination process in a B16BL6 melanoma model. In our study, we show that a single injection of [131I]ICF01012 (ranging from 14.8 to 22.2 MBq) was effective and associated with low and transient haematological toxicity. Concerning pigmented organs, cutaneous melanocytes and skin were undamaged. In 30% of treated animals, no histological alteration of retina was observed, and in the remaining 70%, damages were restricted to the optic nerve area. Using the Medical Internal Radiation Dose methodology, we determined that the absorbed dose in major organs is very low (<4 Gy) and that a delivery of 30 Gy to the tumour is sufficient for an effective anti-tumoural response. Molecular analyses of treated tumours showed a strong radiobiological effect with a decrease in proliferation, survival and pro-angiogenic-related markers and an increase in tumour suppressor gene expression, melanogenesis and anti-angiogenic markers. All these features are in accordance with a tumour cell death mechanism that mainly occurs by mitotic catastrophe and provide a better understanding of in vivo anti-tumoural effects of [131I] radionuclide. Our findings raise [131I]ICF01012 a good candidate for disseminated melanoma treatment and strongly support transfer of [131I]ICF01012 to clinical trial.
Collapse
Affiliation(s)
- Françoise Degoul
- Imagerie Moléculaire et Thérapie Vectorisée, Université d'Auvergne, Clermont Université, Clermont-Ferrand, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Tixier L, Dauplat MM, Le Bouedec G, Lémery S, Bellières A, Mishellany F, Fouilhoux G, Dauplat J, Penault-Llorca F. Facteurs prédictifs de récidive des carcinomes canalaires in situ du sein. Construction d’une série exploratoire pour évaluation dans un essai prospectif (Boost Ou Non Boost dans les cancers canalaires In Situ [BONBIS]). Ann Pathol 2012. [DOI: 10.1016/j.annpat.2012.09.159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
19
|
Tréchot I, Cayre A, Kwiatowski F, Dauplat MM, Abrial C, Mishellany F, Fouilhoux G, Mouret-Reynier MA, Nabholtz JM, Penault-Llorca F. Sub-localisation cellulaire de la P-cadhérine dans les cancers du sein triple négatifs : un marqueur de la transition épithélio-mésenchymateuse ? Ann Pathol 2012. [DOI: 10.1016/j.annpat.2012.09.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
20
|
Dubois V, Delort L, Mishellany F, Jarde T, Billard H, Lequeux C, Damour O, Penault-Llorca F, Vasson MP, Caldefie-Chezet F. Zinc-alpha2-glycoprotein: a new biomarker of breast cancer? Anticancer Res 2010; 30:2919-2925. [PMID: 20683033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
BACKGROUND/AIM Obesity increases the risk of breast cancer. It is established that adipocyte secretions, i.e. adipokines, may play a role in mammary carcinogenesis. We have shown that two major adipokines, leptin and adiponectin, were expressed in mammary adenocarcinoma. PATIENTS AND METHODS Here, we evaluated zinc-alpha2-glycoprotein (ZAG) expression in tumor (n=55) and healthy (n=6) breast tissue by immunohistochemistry and examined whether it was correlated with that of major adipokines, usual tumor biomarkers (sex steroids receptors, i.e. estrogen (ER) and progesterone; Ki-67; cErb2), or apoptosis markers (Bcl2 and Bax). RESULTS ZAG expression was detected in ductal carcinoma and normal epithelial adjacent tissue but not in normal tissue of healthy women. In cancer tissue, its expression was correlated positively to leptin receptor and negatively to adiponectin receptor and ER. CONCLUSION These preliminary results suggest both a relationship between ZAG expression and pathways involving adipokines or estrogen and that ZAG may be a potential breast cancer biomarker.
Collapse
Affiliation(s)
- V Dubois
- Faculté de Pharmacie, Laboratoire SVFp, 28 place Henri-Dunant, B.P. 38, 63000 Clermont-Ferrand, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Bonnet M, Mishellany F, Papon J, Cayre A, Penault-Llorca F, Madelmont JC, Miot-Noirault E, Chezal JM, Moins N. Anti-melanoma efficacy of internal radionuclide therapy in relation to melanin target distribution. Pigment Cell Melanoma Res 2010; 23:e1-11. [PMID: 20444199 DOI: 10.1111/j.1755-148x.2010.00716.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Targeted internal radionuclide therapy (TRT) could be an efficient, specific way to treat disseminated melanoma. Based on a previous pharmacomodulation study, we selected a quinoxaline-derived molecule (ICF01012) for its melanin specificity and kinetic properties suitable for TRT. Here, we determined the efficacy of [(131)I]ICF01012 radiotherapy in vitro and in vivo in relation to melanogenesis using human melanoma models. [(125)I]ICF01012 uptake was first assessed in relation to melanin content. We found that melanin distribution in different models was representative of pathology seen in human tumours: melanin content was high in the extracellular space of SKMel3 tumours, and accumulated primarily in melanophages in M4Beu tumours. Targeted [(131)I]ICF01012 radiotherapy had a strong anti-tumoural efficacy in pigmented versus unpigmented tumours, regardless of target distribution and content. This study supports the use of melanin targeting with (131)I-labelled iodoquinoxaline for effective treatment of melanoma.
Collapse
Affiliation(s)
- M Bonnet
- UMR 990 INSERM/UdA-Imagerie Moléculaire et Thérapie vectorisée, Clermont-Ferrand, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Mathilde B, Papon J, Mishellany F, DeFreitas D, Blavignac C, Cayre A, Donnariex D, Madelmont JC, Chezal JM, Moins N. 2: Évaluation d’une stratégie de radiothérapie vectorisée du mélanome: efficacité anti-tumorale en fonction de la distribution de la cible mélanique. Bull Cancer 2010. [DOI: 10.1016/s0007-4551(15)31095-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Romero P, Dauplat MM, Mishellany F, Gimbergues P, Le Bouëdec G, Penault-Llorca F. Chirurgie conservatrice du cancer du sein: évaluation des berges d’exérèse lors de la chirurgie première. ONCOLOGIE 2010. [DOI: 10.1007/s10269-009-1839-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
24
|
Jardé T, Caldefie-Chézet F, Goncalves-Mendes N, Mishellany F, Buechler C, Penault-Llorca F, Vasson MP. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer 2009; 16:1197-210. [PMID: 19661131 DOI: 10.1677/erc-09-0043] [Citation(s) in RCA: 116] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Obesity is a risk factor for breast cancer development. A recent hypothesis suggests that the adipokines, adiponectin and leptin, are involved in breast cancer development. This prompted us to investigate the role of adiponectin and leptin in mammary carcinogenesis. Adiponectin receptors (AdipoR1 and AdipoR2) and leptin receptor (Ob-Rt, representing all the isoforms of Ob-R) proteins were detected by immunohistochemistry in in situ ductal carcinoma, invasive ductal malignancy, and healthy adjacent tissue. In addition, mRNA expression of adiponectin, AdipoR1, AdipoR2, leptin, Ob-Rt, and Ob-Rl (the long isoform of Ob-R) was observed in MCF-7 breast cancer cells. Interestingly, leptin mRNA expression was 34.7-fold higher than adiponectin mRNA expression in the MCF-7 cell line. Moreover, adiponectin (10 microg/ml) tended to decrease the mRNA expression of leptin (-36%) and Ob-Rl (-28%) and significantly decreased Ob-Rt mRNA level (-26%). In contrast, leptin treatment (1 microg/ml) significantly decreased AdipoR1 mRNA (-23%). Adiponectin treatment (10 microg/ml) inhibited the proliferation of MCF-7 cells, whereas leptin (1 microg/ml) stimulated the growth of cancer cells. In addition, adiponectin inhibited leptin-induced cell proliferation (both 1 microg/ml). Using microarray analysis, we found that adiponectin reduced the mRNA levels of genes involved in cell cycle regulation (mitogen-activated protein kinase 3 and ATM), apoptosis (BAG1, BAG3, and TP53), and potential diagnosis/prognosis markers (ACADS, CYP19A1, DEGS1, and EVL), whereas leptin induced progesterone receptor mRNA expression. In conclusion, the current study indicates an interaction of leptin- and adiponectin-signaling pathways in MCF-7 cancer cells whose proliferation is stimulated by leptin and suppressed by adiponectin.
Collapse
MESH Headings
- Adiponectin/genetics
- Adiponectin/metabolism
- Apoptosis
- Biomarkers, Tumor/genetics
- Biomarkers, Tumor/metabolism
- Blotting, Western
- Breast/metabolism
- Breast/pathology
- Breast Neoplasms/genetics
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/genetics
- Carcinoma, Ductal, Breast/metabolism
- Carcinoma, Ductal, Breast/pathology
- Cell Proliferation
- Female
- Gene Expression Profiling
- Humans
- Immunoenzyme Techniques
- In Vitro Techniques
- Leptin/genetics
- Leptin/metabolism
- Neoplasm Invasiveness
- Oligonucleotide Array Sequence Analysis
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Receptors, Adiponectin/genetics
- Receptors, Adiponectin/metabolism
- Receptors, Leptin/genetics
- Receptors, Leptin/metabolism
- Reverse Transcriptase Polymerase Chain Reaction
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- T Jardé
- Université Clermont 1, UFR Pharmacie, EA4233, CLARA, CRNH-A, Clermont-Ferrand, France.
| | | | | | | | | | | | | |
Collapse
|
25
|
Le Bouëdec G, Mishellany F, Pomel C, Penault-Llorca F. Carcinosarcomes utérins : complications iatrogènes (létales) de l’hormonothérapie des cancers du sein par tamoxifène. Rev Med Interne 2009. [DOI: 10.1016/j.revmed.2009.10.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
26
|
Dauplat J, Chene G, Pomel C, Dauplat M, Bouëdec G, Mishellany F, Lagarde N, Bignon Y, Jaffeux P, Aublet-Cuvelier B, Dechelotte P, Pouly J, Penault-Llorca F. Comparison of dysplasia profiles in stimulated ovaries and in those with a genetic risk for ovarian cancer. Eur J Cancer 2009; 45:2977-83. [DOI: 10.1016/j.ejca.2009.06.012] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2009] [Revised: 06/09/2009] [Accepted: 06/12/2009] [Indexed: 11/24/2022]
|
27
|
Penault-Llorca F, Mishellany F. [Diagnostic pitfalls in mammary pathology. Case 7. Spindle-cell carcinoma of the breast or metaplastic carcinoma]. Ann Pathol 2009; 29:223-7. [PMID: 19619830 DOI: 10.1016/j.annpat.2009.02.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/20/2009] [Indexed: 10/20/2022]
|
28
|
Bonnet-Duquennoy M, Papon J, Mishellany F, Labarre P, Guerquin-Kern JL, Wu TD, Gardette M, Maublant J, Penault-Llorca F, Miot-Noirault E, Cayre A, Madelmont JC, Chezal JM, Moins N. Targeted radionuclide therapy of melanoma: anti-tumoural efficacy studies of a new 131I labelled potential agent. Int J Cancer 2009; 125:708-16. [PMID: 19437532 DOI: 10.1002/ijc.24413] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
In recent years, there has been dramatic worldwide increase in incidence of malignant melanoma. Although localised disease is often curable by surgical excision, metastatic melanoma is inherently resistant to most treatments. In this context, targeted radionuclide therapy could be an efficient alternative. After pharmacomodulation study, we selected a quinoxaline derivative molecule (ICF01012) for its high, specific and long-lasting uptake in melanoma with rapid clearance from nontarget organs providing suitable dosimetry parameters for targeted radiotherapy. Aim of this study was to investigate, in vivo, efficacy of [(131)I]ICF01012 on nonmetastatic B16F0, metastatic B16Bl6 or human M4Beu melanoma tumours. First, colocalisation of ICF01012 with melanin by SIMS imaging was observed. Second, we showed that treatment drastically inhibited growth of B16F0, B16Bl6 and M4beu tumours whereas [(131)I]NaI or unlabelled ICF01012 treatment was without significant effect. Histological analysis and measure of PCNA proliferation marker expression showed that residual B16 tumour cells exhibit a significant loss of aggressiveness after treatment. This effect is associated with a lengthening of the treated-mice survival time. Moreover, with B16Bl6 model, 55% of the untreated mice had lung metastases whereas no metastasis was counted on treated group. Our data demonstrated a strong anti-tumoural effect of [(131)I]ICF01012 for radionuclide therapy on murine and human in vivo pigmented melanoma models, whatever their dissemination profiles and their melanin content be. Further studies will attempt to optimise therapy protocol by increasing the balance between the anti-tumoural effect and the safety on non-target organs.
Collapse
|
29
|
Chêne G, Penault-Llorca F, Le Bouëdec G, Mishellany F, Dauplat MM, Jaffeux P, Aublet-Cuvelier B, Pouly JL, Déchelotte P, Dauplat J. Ovarian epithelial dysplasia and prophylactic oophorectomy for genetic risk. Int J Gynecol Cancer 2009; 19:65-72. [PMID: 19258944 DOI: 10.1111/igc.0b013e3181990127] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
UNLABELLED To make an accurate histopathological description of ovarian dysplasia in a population at genetic risk of ovarian cancer and devise an ovarian dysplasia score. MATERIALS AND METHODS In this retrospective cohort study, 90 patients who had undergone bilateral oophorectomy or ovarian cystectomy between 1992 and 2005 and whose ovaries were reported as normal were divided into two groups: Group A comprising prophylactic oophorectomies for genetic predisposition (N = 28), and Group B or control group, fertile and non-cancerous (N = 62). Eleven epithelial cytological and architectural features were defined. Ovaries were analysed and reviewed by four pathologists blinded to clinical data. An ovarian dysplasia score was devised to quantify extent of ovarian epithelial abnormalities. The degrees of ovarian epithelial abnormalities (dysplasia scores) were compared between the two groups. RESULTS Mean dysplasia score was significantly higher in Group A (prophylactic oophorectomies) than in Group B (control group) (9.67 vs. 4.19, P < 0.001). In Group A, we observed a gradation in the severity of the dysplastic lesions between (i) proven BRCA mutations and prophylactic oophorectomies without mutations (11.26 vs. 8.1), and (ii) according to age (10.27 after age 50 years vs. 8.6 before age 50 years, P = 0.2962). CONCLUSION These results suggest abnormalities in ovaries from high risk women. The ovarian dysplasia may be a pre-malignant, non-invasive histological lesion that could be an important step in early neoplasia.
Collapse
Affiliation(s)
- Gautier Chêne
- Department of Surgery, Centre Jean Perrin, rue Montalembert, Clermont-Ferrand, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Jardé T, Caldefie-Chézet F, Damez M, Mishellany F, Perrone D, Penault-Llorca F, Guillot J, Vasson MP. Adiponectin and leptin expression in primary ductal breast cancer and in adjacent healthy epithelial and myoepithelial tissue. Histopathology 2009; 53:484-7. [PMID: 18983614 DOI: 10.1111/j.1365-2559.2008.03121.x] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
31
|
Penault-Llorca F, Abrial C, Raoelfils I, Chollet P, Cayre A, Mouret-Reynier MA, Thivat E, Mishellany F, Gimbergues P, Durando X. Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 2008; 13:1235-45. [PMID: 19091781 DOI: 10.1634/theoncologist.2008-0073] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
The current study expands upon previous work using a database of 710 patients treated with neoadjuvant chemotherapy. First, we studied phenotypic characteristics of tumors before and after chemotherapy using the following factors: the mitotic index of the Scarff-Bloom-Richardson grade, Ki-67, cyclin D1, and cyclo-oxygenase-2. Second, the predictive value of these factors on response was assessed. Third, we measured the prognostic impact of these markers post-therapy in comparison with clinical and pathological responses according to the Chevallier and Sataloff classifications. Patients were treated using different neoadjuvant chemotherapy combinations, mainly in successive prospective phase II trials. They received a median number of six cycles (range, 1-9). After neoadjuvant chemotherapy, patients underwent surgery and radiotherapy. In cases of important residual disease, some received additional courses of chemotherapy. In addition, menopausal patients with hormone receptor-positive tumors received tamoxifen for 5 years. According to our analysis, we found significant variations before and after neoadjuvant chemotherapy only for cyclin D1 and the mitotic index. Concerning the predictive value of biomarkers for response, Ki-67 and the mitotic index were predictive on univariate analysis, both for objective clinical and pathological complete responses. Because these two factors were correlated, no multivariate analyses were conducted. We then assessed the prognostic impact of the biopathological factors. When the factors were measured before chemotherapy, all were prognostic. When evaluated after chemotherapy, the mitotic index, objective clinical response, and pathological complete response were prognostic. Because these factors were correlated, no multivariate model was done. The main clinical fact is that there were significant correlations between clinical and pathological responses and variations in the biological factors studied.
Collapse
|
32
|
Chene G, Penault-Llorca F, Le Bouedec G, Mishellany F, Dauplat M, Jaffeux P, Aublet-Cuvelier B, Pouly J, Dechelotte P, Dauplat J. Ovarian epithelial dysplasia after ovulation induction: time and dose effects. Hum Reprod 2008; 24:132-8. [DOI: 10.1093/humrep/den358] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
Chêne G, Penault-Llorca F, Le Bouëdec G, Mishellany F, Dauplat MM, Tardieu AS, Pomel C, Jaffeux P, Aublet-Cuvelier B, Pouly JL, Déchelotte P, Dauplat J. [Ovarian epithelial dysplasia: myth or reality? Review]. ACTA ACUST UNITED AC 2008; 36:800-7. [PMID: 18657463 DOI: 10.1016/j.gyobfe.2008.05.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2008] [Accepted: 05/27/2008] [Indexed: 10/21/2022]
Abstract
Ovarian epithelial dysplasia has been described in the ovarian surface epithelium by histologic, morphometric and nuclear profile studies. It could represent a potential precursor of ovarian malignancy in patients with genetic risk of ovarian cancer, although its natural history and progression to carcinoma are unpredictable. Diagnosis and identification of ovarian dysplasia would certainly be useful to understand the early steps of ovarian carcinogenesis. However, dysplasia in relation with ovulation induction seems to have a different pattern. We report dysplasia definitions and the current clinical management.
Collapse
Affiliation(s)
- G Chêne
- Département de chirurgie, centre Jean-Perrin, rue Montalembert, 63000 Clermont-Ferrand, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Jardé T, Caldefie-Chézet F, Damez M, Mishellany F, Penault-Llorca F, Guillot J, Vasson MP. Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. Oncol Rep 2008. [PMID: 18357374 DOI: 10.3892/or.19.4.905] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
Obesity is associated with an increased risk of breast cancer. Leptin, a hormone synthesised essentially by adipose tissue, may be involved in cancer development. We examined the expression of leptin and leptin receptor (Ob-R) in human primary breast cancer and adjacent non-cancerous tissue. We also analysed their relationships with histological variables such as the oestrogen and progesterone receptors, Ki67 proliferation factor and tumour size. The expressions of leptin and Ob-R were investigated by immunohistochemical staining in 35 primary breast cancers and 17 adjacent non-cancerous tissues. Samples and histological features were obtained from the Anti-Cancer Centre. Expressions of leptin and Ob-R were detected in, respectively, 85 and 75% of the primary breast cancer cases studied. The expression of leptin was significantly correlated with Ob-R detection (p=0.008). In addition, Ob-R expression in primary breast carcinoma was positively correlated with oestrogen receptor expression (p=0.028) and tumour size (p=0.045) but not with Ki67 or progesterone receptor expressions. However, the expression of leptin showed no statistical correlation with these variables. First, the co-expression of leptin and Ob-R in primary breast cancer shows that leptin acts on mammary tumour cells via an autocrine pathway. Second, the co-expression of Ob-R and oestrogen receptors suggests a possible interaction between leptin and oestrogen systems to promote breast carcinogenesis. Finally, the fact that Ob-R expression was positively correlated with tumour size may point to a potential role of leptin as a growth factor and of Ob-R as a new prognostic factor.
Collapse
Affiliation(s)
- Thierry Jardé
- UFR Pharmacie, Université Clermont 1, EA2416, France.
| | | | | | | | | | | | | |
Collapse
|
35
|
Devoize L, Collangettes D, Le Bouëdec G, Mishellany F, Orliaguet T, Dallel R, Baudet-Pommel M. Giant mature ovarian cystic teratoma including more than 300 teeth. ACTA ACUST UNITED AC 2008; 105:e76-9. [PMID: 18280952 DOI: 10.1016/j.tripleo.2007.10.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2007] [Revised: 08/25/2007] [Accepted: 10/01/2007] [Indexed: 11/29/2022]
Abstract
Preoperative diagnosis of malignant tumors arising from mature cystic teratoma (MCT) of the ovary is not easy; malignant tumors are mostly diagnosed only postoperatively. Tumor size, serum tumor markers, and patient age have been proposed as risk factors for malignancy. This article reports a rare case of a giant, benign MCT of the ovary in a young woman (25 years old). It had a very large size (320 x 270 x 185 mm, 10 kg), a great number of teeth (> 300), and preoperative serum level of tumor markers were elevated (CA125, 875 U/mL(-1); CA19-9, 2087 U/mL(-1); CEA, 5.1 ng/mL(-1); AFP, 23.3 ng/mL(-1); SCC, 20.7 ng/mL(-1)). Based on clinical and laboratory data, tumor markers and tumor size when used alone or in combination do not appear to be useful in making a differential diagnosis between MCT and squamous cell carcinoma arising from MCT. However, radiologically detectable, well-differentiated teeth may be indicative of benignity.
Collapse
|
36
|
Cayre A, Mishellany F, Lagarde N, Penault-Llorca F. Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification. Breast Cancer Res 2008; 9:R64. [PMID: 17908324 PMCID: PMC2242659 DOI: 10.1186/bcr1770] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2007] [Revised: 07/30/2007] [Accepted: 10/01/2007] [Indexed: 11/21/2022] Open
Abstract
Introduction Accurate determination of human epidermal growth factor receptor 2 (HER2) status is essential for optimal patient management with trastuzumab (Herceptin). However, standard guidelines do not specify a particular commercial kit, antibody or probe for testing, and discrepancies arise from variability between kits. The aim of this study was to compare the accuracy of four commercially available fluorescence/chromogenic in situ hybridisation (FISH/CISH) kits and validate one for the resolution of borderline immunohistochemistry (IHC) cases. The interpretation pitfalls, optimal threshold values, assay duration and complexity of each kit were also considered. Methods The Food and Drug Administration (FDA)-approved dual-probe FISH assay PathVysion was chosen as the 'gold standard' against which pharmDx (dual-probe) and INFORM (mono-probe) FDA-approved FISH kits and the SPoT-Light CISH kit were compared. Tumours were also evaluated by IHC with the FDA-approved HercepTest kit and a validated in-house IHC protocol. Fifty-five patients with invasive breast carcinoma were selected as a representative proportion of HER2 IHC 2+ cases. Results HER2 amplification was observed in 31% of tumours by PathVysion compared with 33% with pharmDx. The number of amplified tumours detected by INFORM and CISH varied with the threshold applied. Agreement was excellent between PathVysion and pharmDx (100%), good with SPoT-Light (89%; cutoff at least five signals per nucleus) and moderate with INFORM (76%; cutoff more than four signals per nucleus). Agreement with INFORM improved to 98% with a cutoff of at least six signals per nucleus. Conclusion With an appropriate cutoff, the INFORM kit was comparable to dual-probe FISH kits for evaluating HER2 status. We validate and recommend CISH as an appropriate assay for HER2 scoring that is easy to interpret and requires equipment readily found in, or that can be adapted to, all pathology laboratories. For borderline IHC cases, dual-probe FISH analysis remains the most useful protocol to apply.
Collapse
Affiliation(s)
- Anne Cayre
- Département de Pathologie, Centre Jean Perrin, 58 Rue Montalembert, BP392, 63011 Clermont-Ferrand Cédex, France
- Inserm UMR 484, Rue Montalembert, BP184, 63005 Clermont-Ferrand, France
- Institut Universitaire de Technologie, Ensemble Universitaire des Cézeaux, BP 86, 63170 Aubière, France
| | - Florence Mishellany
- Département de Pathologie, Centre Jean Perrin, 58 Rue Montalembert, BP392, 63011 Clermont-Ferrand Cédex, France
- Inserm UMR 484, Rue Montalembert, BP184, 63005 Clermont-Ferrand, France
| | - Nicole Lagarde
- CHU Hôpital Morvan, 5 Avenue Foch, 29609 Brest Cédex, France
| | - Frédérique Penault-Llorca
- Département de Pathologie, Centre Jean Perrin, 58 Rue Montalembert, BP392, 63011 Clermont-Ferrand Cédex, France
- Inserm UMR 484, Rue Montalembert, BP184, 63005 Clermont-Ferrand, France
- Université d'Auvergne, Faculté de Médecine, 28 Place Henri Dunant, BP 38, 63000 Clermont-Ferrand, France
| |
Collapse
|
37
|
Le Bouëdec G, de Lapasse C, Mishellany F, Chêne G, Michy T, Gimbergues P, Dauplat J. Cancer canalaire in situ du sein avec micro-invasion. Place du ganglion sentinelle. ACTA ACUST UNITED AC 2007; 35:317-22. [PMID: 17344087 DOI: 10.1016/j.gyobfe.2006.12.024] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2006] [Accepted: 12/15/2006] [Indexed: 10/23/2022]
Abstract
OBJECTIVES To investigate the role of sentinel lymph node biopsy for microinvasive ductal carcinoma in situ of the breast. PATIENTS AND METHODS From January 2001 to January 2006, lymphatic mapping was performed using radiocolloid and/or blue dye technique. Full axillary lymph node dissection was accomplished systematically in 10 instances at the beginning of the study, and furthermore when the sentinel node was involved (macrometastatic or micrometastatic disease). RESULTS Identification rate was 98% (40/41), the unsuccessful procedure occurred after incisional biopsy for diagnosis. The number of sentinel nodes removed was 2 in average (1-5). Sentinel node involvement was found in 10% of cases (4/40): 1 sentinel node macrometastasis pN1, 2 sentinel node micrometastases determined by hematoxylin and eosin staining pN1 (mi), 1 sentinel node micrometastasis detected only by immunohistochemical staining pN0 (mi). DISCUSSION AND CONCLUSION Sentinel lymph node sampling should not be currently applied for management of every ductal carcinoma in situ of the breast but a selective utilization is proposed in documented high risk subset of patients according to clinical, mammographic, and histologic features obtained by percutaneous biopsies. Ductal carcinoma in situ (DCIS) with proved or suspected microinvasion could be scheduled for sentinel node procedure a fortiori in cases undergoing mastectomy because of extensive DCIS before the occurrence of disturbances of lymphatic drainage induced by surgical breast dissection.
Collapse
Affiliation(s)
- G Le Bouëdec
- Service de chirurgie, centre Jean-Perrin (centre de lutte contre le cancer d'Auvergne), 58, rue Montalembert, BP 392, 63011 Clermont-Ferrand cedex 01, France.
| | | | | | | | | | | | | |
Collapse
|
38
|
Bay JO, Cabrespine A, Gilliot O, Bailly C, Vincent C, Mishellany F, Gimbergues P. [Docetaxel and gemcitabine combination in soft-tissue sarcomas treatment]. Bull Cancer 2007; 94 Spec No Actualites:S122-6. [PMID: 17845981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
Soft-tissue sarcomas (STS) are usually sensitive to doxorubicine and/or ifosfamide. When tumors become refractory to these two drugs, chemotherapeutic options are limited. All the drugs tested generally yield occasional or negligible response, with response rates lower than 20% and a poor duration of response. No second-line chemotherapy have been clearly adopted. In vitro synergistic cytotoxicity has been reported with gemcitabine and docetaxel combination. Promising anti-tumor activity has been described with gemcitabine alone, docetaxel alone or these two drugs in combination These treatments were generally well tolerated. The best response have been observed in leiomyosarcomas. According to these results, gemcitabine and docetaxel combination might be of interest in STS. However, a phase III study is required to better evaluate the real advantage of this treatment.
Collapse
|
39
|
Abstract
The knowledge of the axillary involvement is a major prognosis factor for breast cancer and an important parameter for treatment decision. Nevertheless, two recent current medical situations have occurred in breast cancer, changing our management. First, with the development of mass screening and sentinel lymph nodes biopsies, we have to take treatment decisions based upon minimal lymph node involvement, with a clinical significance still poorly understood. Second, for the large tumors, potentially with lymph node involvement, we have to deal with tumor and lymph node under staging, after induction chemotherapy. We have to learn how to evaluate accurately those new parameters to treat the best way our patients.
Collapse
Affiliation(s)
- F Penault-Llorca
- Département de Pathologie, Centre Jean-Perrin, 58, Rue Montalembert, BP 392, 63011 Clermont-Ferrand Cedex 01, France.
| | | |
Collapse
|
40
|
Peffault de Latour R, Dujardin HC, Mishellany F, Burlen-Defranoux O, Zuber J, Marques R, Di Santo J, Cumano A, Vieira P, Bandeira A. Ontogeny, function, and peripheral homeostasis of regulatory T cells in the absence of interleukin-7. Blood 2006; 108:2300-6. [PMID: 16763207 DOI: 10.1182/blood-2006-04-017947] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Mice lacking interleukin-7 (IL-7-/- mice) have no signs of autoimmune disease, contrary to other models of lymphopenia. We investigated whether the absence of disease was due to the fact that IL-7 is dispensable for the ontogeny, function, and homeostasis of regulatory CD4+ T cells. We show here that the establishment of the peripheral pool of Foxp3-expressing regulatory cells is IL-7 independent, and the premature involution of the thymus in IL-7-/- mice does not change the representation of the CD4+CD25+ T-cell compartment. In addition, CD4+CD25+ T cells expand in the absence of IL-7, without losing Foxp3 expression. The frequency of activated peripheral CD4+ T cells increases with age in both the CD25- and CD25+ compartments, with the CD4+CD25+ T cells displaying signs of constant activation. IL-7-/- CD4+CD25+ T cells control inflammatory bowel disease induced by IL-7-/- T cells even in hosts lacking IL-7. Depletion of the CD25+ T-cell subset after thymic involution results in a mild form of inflammatory bowel disease (IBD), which resolves concomitantly with the regeneration of this subset. This study shows for the first time that IL-7-/- mice have a robust regulatory Foxp3-expressing CD4+ T-cell compartment that controls T-cell-mediated disease. It also highlights the potential of the regulatory Foxp3-expressing CD4+CD25- T-cell population to restore a functional CD4+CD25+ T-cell compartment through an IL-7-independent pathway.
Collapse
|
41
|
Michy T, Le Bouëdec G, Mishellany F, Penault-Llorca F, Dauplat J. [Is there still a place for extemporaneous exam in breast cancer?]. ACTA ACUST UNITED AC 2006; 34:115-9. [PMID: 16483825 DOI: 10.1016/j.gyobfe.2005.12.020] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2005] [Accepted: 12/05/2005] [Indexed: 10/25/2022]
Abstract
OBJECTIVE The rise of preoperative diagnosis thanks to new methods of micro and macrobiopsy and the development of sentinel lymph node have dramatically modified the surgical management of patients with breast tumor. The purpose of this study is to know if extemporaneous exams still have a place in the management of breast cancer. PATIENTS AND METHODS Retrospective study which compares the qualitiative evolution of frozen sections in breast tumor at Jean-Perrin center before the practice of percutaneous strereotaxic biopsy and after the training of sentinel lymph node operative biopsy. RESULTS The results were in favour of a different distribution of anatomocytopathological activity with a decrease of frozen section in breast tumor and an increase of cytological imprints on sentinel nodes. DISCUSSION AND CONCLUSION The interest of histologic preoperative diagnosis and the failure of consensus in the sentinel lymph node just leave a restrictive position to frozen section in breast cancer.
Collapse
Affiliation(s)
- T Michy
- Service de chirurgie carcinologique, centre Jean-Perrin, place Henri-Dunant, 63000 Clermont-Ferrand, France.
| | | | | | | | | |
Collapse
|
42
|
Mishellany F, Roelfils I, Penault-Llorca F. Que sait-on de la carcinogenèse ovarienne? ONCOLOGIE 2006. [DOI: 10.1007/s10269-006-0346-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
43
|
Mishellany F, Dauplat MM, Vernerey F, Fouilhoux G, Penault-Llorca F. [An inflammatory tumor-like lesion of the breast]. Ann Pathol 2003; 23:613-4. [PMID: 15094601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Affiliation(s)
- Florence Mishellany
- Département de Pathologie, Centre Jean Perrin, 58 Rue Montalembert, BP 392, 63011 Clermont-Ferrand Cedex 1
| | | | | | | | | |
Collapse
|
44
|
Dauplat MM, Mishellany F, Delatour M, Penault-Llorca F. [An aggressive subtype of breast carcinoma]. Ann Pathol 2003; 23:611-2. [PMID: 15094600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Affiliation(s)
- Marie-Mélanie Dauplat
- Département de Pathologie, Centre Jean Perrin, 58 Rue Montalembert, BP 392, 63011 Clermont-Ferrand Cedex 1
| | | | | | | |
Collapse
|